AbbVie Inc vs Dollar General Corp. — how do they compare? AbbVie Inc trades at $265.52 (market cap $466.45B), while Dollar General Corp. trades at $123.37 (market cap $27.01B). The key difference: AbbVie Inc is far larger — about 17.3× Dollar General Corp.'s market cap, and AbbVie Inc pays the higher dividend (2.62%). Which is the better fit depends on your goals — on Pluang, investors hold AbbVie Inc for 93 Days and Dollar General Corp. for 58 Days on average.
| ABBV | DG | |
|---|---|---|
Market Cap | $466.45B | $27.01B |
Volume | 7,981,281 | 4,695,567 |
Sector | Health | Consumer Staples |
52-Week High | $265.97 | $156.26 |
52-Week Low | $197.38 | $95.94 |
Typical Hold Time | 93 Days | 58 Days |
Enterprise Value | $530.70B | $41.19B |
Dividend Yield | 2.62% | 1.93% |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $263.78, showing minimal daily movement (-0.08%) with strong technical bullish signals from moving averages. The company demonstrates robust revenue growth, reaching $61.16B in 2025, with consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 72% buy ratings and a $287.08 consensus price target, representing 8.8% upside potential. Recent positive clinical trial results for ELAHERE in ovarian cancer and strong performance from Skyrizi and Rinvoq offsetting Humira declines highlight ongoing portfolio transformation.
AbbVie presents a compelling investment case with strong fundamentals, dividend growth, and successful navigation of patent cliffs, though elevated valuation ratios and long-term patent risks require monitoring. The stock's current technical positioning near pivot point support at $263 suggests potential for upward movement toward resistance at $265, supported by institutional accumulation and positive earnings momentum.
Dollar General (DG) trades at $122.545, up 0.12% on the day, with a bearish technical signal but strong recent earnings beats. The stock shows attractive valuation with a P/E of 15.9 and P/S of 0.62, while profitability metrics like ROE of 19.69% remain solid. Recent news highlights institutional buying and value-focused growth initiatives amid consumer pressure.
The outlook is cautiously positive with a consensus price target of $135.64 offering ~11% upside, supported by earnings momentum and margin recovery efforts. Key risks include competitive pressures and macroeconomic sensitivity, but analyst sentiment leans bullish with 52% buy ratings. Cash flow stability and debt reduction trends provide fundamental support.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →